Date：27 July (Wednesday)
Time: 14:00 – 15:30 (GMT+8)
George Yeh joined TLC in 2002 as President and leads the Company’s operations. George is responsible for strategic planning of the Company’s drug programs, business operations, corporate development, product licensing, and management of corporate funding. With George’s ability to organize and lead the capable team, TLC flourished into one of the fastest‐growing drug delivery companies in Asia. TLC was named one of the Top 100 Private Companies by Red Herring Asia in 2006 and shortlisted for Red Herring Global in 2007.
Gorge received the “Outstanding Young Innovator Award” in 2008 for his contribution to the biotechnology industry in Taiwan. Under George’s guidance, the TLC team worked collectively toward an initial public offering (IPO) on the Taipei Exchange in 2012, followed by an IPO on Nasdaq in 2018, becoming the first Taiwan-based biotech company to have achieved such an accomplishment.
TLC was consistently ranked in the Top 5% in Corporate Governance Evaluations every year until the company went private in 2021.
George was most recently CFO of Hermes Biosciences, assisting to structure and negotiate technology transfer and license contracts with pharmaceutical companies.
Prior to joining Hermes, George was Vice President of AsiaWired Group, where he was responsible for procuring corporate funding, strategic planning, and integration of high‐level management and financial resources for start‐ups.
At AsiaWired Group, George successfully assisted Presenter, Calimetrics and other high-tech companies with fundraising and planned Asian expansions for several US‐based companies.
Before coming to AsiaWired Group, George was an associate at General Bank, evaluating start‐ups and venture capital partnership for debt financing.
George holds a B.A. from the University of California at Berkeley, and a M.A. and a M.B.A. from the University of Michigan – Ann Arbor.